Search results for "GiST"

showing 10 items of 3463 documents

Survival of male genital cancers (prostate, testis and penis) in Europe 1999-2007: Results from the EUROCARE-5 study

2015

Abstract Background We provide updated estimates of survival and survival trends of male genital tumours (prostate, testicular and penis cancers), in Europe and across European areas. Methods The complete approach was used to obtain relative survival estimates for patients diagnosed in 2000–2007, and followed up through 2008 in 29 countries. Data came from 87 cancer registries (CRs) for prostate tumours and from 86 CRs for testis and penis tumours. Relative survival time trends in 1999–2007 were estimated by the period approach. Data came from 49 CRs in 25 countries. Results We analysed 1,021,275 male genital cancer cases. Five-year relative survival was high and decreased with increasing a…

OncologyCancer Researchmedicine.medical_specialtySurvivalRelative survivalbusiness.industryCancer registrieIncidence (epidemiology)ProstateCancerPenile cancermedicine.diseaseProstate cancermedicine.anatomical_structureOncologyProstateInternal medicineCancer registries; Penile cancers; Prostate; Survival; Survival trends; TesticularSurvival trendmedicineTesticularPenile cancerbusinessPenisTesticular cancer
researchProduct

Radiomic analysis reveals DCE-MRI features for prediction of molecular subtypes of breast cancer.

2017

The purpose of this study was to investigate the role of features derived from breast dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and to incorporated clinical information to predict the molecular subtypes of breast cancer. In particular, 60 breast cancers with the following four molecular subtypes were analyzed: luminal A, luminal B, human epidermal growth factor receptor-2 (HER2)-over-expressing and basal-like. The breast region was segmented and the suspicious tumor was depicted on sequentially scanned MR images from each case. In total, 90 features were obtained, including 88 imaging features related to morphology and texture as well as dynamic features from tumor and …

OncologyCancer Treatmentlcsh:MedicineInvasive Ductal CarcinomaLogistic regression030218 nuclear medicine & medical imagingDiagnostic Radiology0302 clinical medicineMathematical and Statistical TechniquesBreast TumorsImage Processing Computer-AssistedMedicine and Health Scienceslcsh:ScienceMultidisciplinarymedicine.diagnostic_testHuman epidermal growth factorRadiology and ImagingMiddle AgedMagnetic Resonance ImagingOncology030220 oncology & carcinogenesisArea Under CurvePhysical SciencesFemaleAlgorithmsStatistics (Mathematics)Research ArticleAdultmedicine.medical_specialtyImaging TechniquesImage processingBreast NeoplasmsResearch and Analysis MethodsCarcinomasSkewness03 medical and health sciencesBreast cancerText miningDiagnostic MedicineInternal medicineImage Interpretation Computer-AssistedBreast CancermedicineBiomarkers TumorHumansStatistical MethodsDifferentiated TumorsAgedNeoplasm StagingReceiver operating characteristicbusiness.industrylcsh:RCancers and NeoplasmsMagnetic resonance imagingLuminal amedicine.diseaseImage EnhancementProbability TheoryProbability Distributionlcsh:QNeoplasm GradingbusinessMathematicsForecastingPloS one
researchProduct

Survival variations by country and age for lymphoid and myeloid malignancies in Europe 2000–2007: Results of EUROCARE-5 population-based study

2015

BACKGROUND: Significant advances in the management of patients with lymphoid and myeloid malignancies entered clinical practice in the early 2000's. The EUROCARE-5 study database provides an opportunity to assess the impact of these changes at the population level by country in Europe. We provide survival estimates for clinically relevant haematological malignancies (HM), using the International Classification of Diseases for Oncology 3, by country, gender and age in Europe. METHODS: We estimated age-standardised relative survival using the complete cohort approach for 625, 000 adult patients diagnosed in 2000-2007 and followed up to 2008. Survival information was provided by 89 participati…

OncologyCancer registry; Europe; Hodgkin lymphoma; Leukaemia; Lymphoma; Multiple myeloma; Non-Hodgkin lymphoma; Relative survivalCancer Researcheducation.field_of_studymedicine.medical_specialtyMyeloidRelative survivalbusiness.industryPopulationFollicular lymphomaPlasma cell neoplasmmedicine.diseaseLymphomaCancer registrymedicine.anatomical_structureOncologyhemic and lymphatic diseasesInternal medicineImmunologyMedicineeducationbusinessInternational Classification of Diseases for OncologyEuropean Journal of Cancer
researchProduct

Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study.

2010

Summary Background Knowledge about the distribution of human papillomavirus (HPV) genotypes in invasive cervical cancer is crucial to guide the introduction of prophylactic vaccines. We aimed to provide novel and comprehensive data about the worldwide genotype distribution in patients with invasive cervical cancer. Methods Paraffin-embedded samples of histologically confirmed cases of invasive cervical cancer were collected from 38 countries in Europe, North America, central South America, Africa, Asia, and Oceania. Inclusion criteria were a pathological confirmation of a primary invasive cervical cancer of epithelial origin in the tissue sample selected for analysis of HPV DNA, and informa…

OncologyInternational CooperationUterine Cervical NeoplasmsPolymerase Chain ReactionHuman papillomaviruses ; cervical cancer0302 clinical medicineGenotypeMass ScreeningYoung adult10. No inequalityPapillomaviridaeCervical cancerAged 80 and over0303 health sciencesParaffin Embeddingmedicine.diagnostic_testAge FactorsMiddle Aged3. Good healthOncology030220 oncology & carcinogenesisCarcinoma Squamous CellFemaleAdultmedicine.medical_specialtyAdolescentGenotypeHPV vaccinesAdenocarcinoma03 medical and health sciencesCarcinoma AdenosquamousYoung AdultInternal medicinemedicineHumansNeoplasm InvasivenessGenetic TestingPapillomavirus VaccinesGenotyping030304 developmental biologyGenetic testingAgedRetrospective StudiesGynecologybusiness.industryPapillomavirus InfectionsBasic Medical Sciencesmedicine.diseaseCross-Sectional StudiesLogistic ModelsBIOMEDICINE AND HEALTHCAREDNA ViralLinear Array HPV Genotyping TestLinear ModelsCervarixbusinessThe Lancet. Oncology
researchProduct

The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells.

2007

BACKGROUND. Clonal cytogenetic abnormalities (CCA) were detected in Philadelphia chromosome (Ph)-negative cells in some patients with chronic myeloid leukemia (CML) who attained a cytogenetic response to imatinib mesylate. In some patients, CCA/Ph-negative status was associated with myelodysplasia or acute myeloid leukemia. The objective of the current study was to determine the prognostic impact of CCA/Ph-negative cells. METHODS. The authors compared the pretherapeutic risk factors (Kruskall-Wallis test), exposure to cytotoxic drugs (chi-square test), and overall and progression-free survival (Kaplan-Meyer and logistic regression analysis, respectively) of 515 patients with mostly chronic-…

OncologyMaleCancer ResearchMyeloidKaplan-Meier EstimatePiperazineshemic and lymphatic diseasesTreatment FailureAged 80 and overMyeloid leukemiaMiddle AgedPrognosisLeukemiamedicine.anatomical_structureTreatment OutcomeOncologyBenzamidesCytogenetic AnalysisImatinib MesylateFemalemedicine.drugAdultmedicine.medical_specialtyNeutropeniaAntineoplastic AgentsPhiladelphia chromosomeDisease-Free SurvivalLeukemia Myeloid Chronic Atypical BCR-ABL Negativechronic myeloid leukemiaInternal medicineparasitic diseasesmedicineHumansAgedChromosome AberrationsChi-Square Distributionbusiness.industryMyelodysplastic syndromesCancerInterferon-alphaImatinibmedicine.diseaseThrombocytopeniaImatinib mesylateLogistic ModelsPyrimidinesMyelodysplastic SyndromesChronic DiseaseCancer researchbusinessFollow-Up StudiesCancer
researchProduct

Second primary cancers after cancer of unknown primary in Sweden and Germany: efficacy of the modern work-up.

2012

In unsparing efforts to find the hidden primaries, second primary cancers (SPCs) unrelated to cancer of unknown primary (CUP) are found. The detection rates of SPCs after CUP can be considered as measures for the effectiveness of modern diagnostic techniques in finding tumors. We aimed to compare the rates of specific SPCs found after the work-up of CUP and the more sign/symptom-directed diagnostic approaches applied after any other cancer. The number of CUP patients identified in the nationwide Swedish database and nine German cancer registries was 24 641 from 1997 through 2006, and rate ratios (RRs) for SPCs were recorded in two follow-up periods. The detection rate of SPCs immediately af…

OncologyMaleCancer Researchmedicine.medical_specialtyDatabases FactualEpidemiologySecond Primary CancersProstateInternal medicineGermanymedicineHumansRegistriesAgedAged 80 and overSwedenUrinary bladderLungbusiness.industryPublic Health Environmental and Occupational HealthCancerNeoplasms Second PrimaryMiddle Agedmedicine.diseaseWork-upLymphomaSurgerymedicine.anatomical_structureTreatment OutcomeOncologyCancer of unknown primaryNeoplasms Unknown PrimaryFemalebusinessFollow-Up StudiesEuropean journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
researchProduct

Multi-state relative survival modelling of colorectal cancer progression and mortality.

2015

Abstract Accurate identification of factors associated with progression of colorectal cancer remains a challenge. In particular, it is unclear which statistical methods are most suitable to separate the effects of putative prognostic factors on cancer progression vs cancer-specific and other cause mortality. To address these challenges, we analyzed 10 year follow-up data for patients who underwent curative surgery for colorectal cancer in 1985–2000. Separate analyses were performed in two French cancer registries. Results of three multivariable models were compared: Cox model with recurrence as a time-dependent variable, and two multi-state models, which separated prognostic factor effects …

OncologyMaleCancer Researchmedicine.medical_specialtyEpidemiologyColorectal cancer01 natural sciencesCancer recurrence010104 statistics & probability03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicinemedicineHumansRegistries0101 mathematicsStage (cooking)AgedNeoplasm StagingModels StatisticalMulti stateRelative survivalbusiness.industryProportional hazards modelCancermedicine.diseasePrognosis3. Good healthSurgerySurvival RateOncology030220 oncology & carcinogenesisCurative surgeryDisease ProgressionFemaleNeoplasm Recurrence LocalbusinessColorectal NeoplasmsCancer epidemiology
researchProduct

Time trends of cancer incidence in European children (1978-1997): Report from the Automated Childhood Cancer Information System project.

2006

Within the framework of the Automated Childhood Cancer Information System (ACCIS), time trend analyses for childhood cancer were performed using data from 33 population-based cancer registries in 15 European countries for the period 1978-1997. The overall incidence rate based on 77,111 cases has increased significantly (P<0.0001), with an average annual percentage change (AAPC) of 1.1%. The rising trend was observed in all five geographical regions and in the majority of the disease groups (in order of AAPC): soft tissue sarcomas (1.8%), brain tumours, tumours of the sympathetic nervous system, germ-cell tumours, carcinomas, lymphomas, renal tumours, and leukaemias (0.6%). No change was see…

OncologyMaleCancer Researchmedicine.medical_specialtyPediatricsTime FactorsAdolescentDatabases FactualPopulationChildhood cancerDiseaseInternal medicineNeoplasmsEpidemiologymedicineHumansRegistrieseducationChildeducation.field_of_studyTime trends - cancer incidence - European childrenbusiness.industryRetinoblastomaIncidence (epidemiology)IncidenceInfant NewbornCancerInfantmedicine.diseaseEuropeOncologyEl NiñoChild PreschoolFemalesense organsbusiness
researchProduct

Human papillomavirus infections and upper aero-digestive tract cancers: the ARCAGE study.

2013

Human papillomavirus (HPV) is causally implicated in a subset of cancers of the upper aero-digestive tract (UADT). Methods Associations between type-specific HPV antibodies were examined among 1496 UADT cancer case subjects and 1425 control subjects by estimating odds ratios (ORs) in logistic regression analyses adjusted for potential confounders. The agreement between serology and tumor markers of HPV infection, including presence of HPV DNA and p16 expression, were examined in a subset of tumors. Results HPV16 L1 seropositivity was associated with increased risk of oral cavity and oropharyngeal cancer (OR = 1.94, 95% confidence interval [CI] = 1.03 to 3.65; OR = 8.60, 95% CI = 5.21 to 14.…

OncologyMaleCancer Researchmedicine.medical_specialtyvirusesPapillomavirus E7 ProteinsFluorescent Antibody TechniqueBiologyAntibodies ViralPolymerase Chain ReactionSerologyInternal medicinemedicineBiomarkers TumorOdds RatioHumansLaryngeal NeoplasmsAgedNeoplasm StagingHuman papillomavirus 16ConfoundingPapillomavirus InfectionsCase-control studyHPV infectionCancervirus diseasesOdds ratioOncogene Proteins ViralMiddle Agedmedicine.diseasefemale genital diseases and pregnancy complicationsUp-RegulationRepressor ProteinsOropharyngeal NeoplasmsOropharyngeal NeoplasmLogistic ModelsOncologyCase-Control StudiesImmunologyHuman papillomavirus 16; Oropharyngeal Neoplasms; Papillomavirus InfectionsDNA ViralEtiologyFemaleJournal of the National Cancer Institute
researchProduct

Prophylactic cranial irradiation in stage IV small cell lung cancer

2019

Background: Due to conflicting results between major trials the role of prophylactic cranial irradiation (PCI) in stage IV small cell lung cancer (SCLC) is controversial.Methods: We obtained a list of 13 European experts from both the European Society for Therapeutic Radiation Oncology (ESTRO) and the International Association for the Study of Lung Cancer (IASLC). The strategies in decision making for PCI in stage IV SCLC were collected. Decision trees were created representing these strategies. Analysis of consensus was performed with the objective consensus methodology.Results: The factors associated with the recommendation for the use of PCI included the fitness of the patient, young age…

OncologyMaleESTRO; Expert opinion; IASLC; PCI; Small cell lung cancer; Stage IV; Hematology; Oncology; Radiology Nuclear Medicine and ImagingLung Neoplasmsmedicine.medical_treatmentMedizin030218 nuclear medicine & medical imaging0302 clinical medicineQUALITY-OF-LIFENuclear Medicine and ImagingESTRO610 Medicine &amp; healthStage IVHematologyBrain NeoplasmsRadiation OncologistsPCIHematologyMiddle AgedProgression-Free SurvivalExpert opinion030220 oncology & carcinogenesisFemaleTRIALNon small cellRadiologyAdultmedicine.medical_specialtyDecision Making03 medical and health sciencesInternal medicinemedicineHumansIASLCRadiology Nuclear Medicine and imagingLung cancerAgedNeoplasm StagingChemotherapySmall cell lung cancerbusiness.industryPatient Selectionmedicine.diseaseONCOLOGYSmall Cell Lung CarcinomaYoung ageConventional PCIProphylactic cranial irradiationCranial IrradiationbusinessStage ivRadiotherapy and Oncology
researchProduct